Search
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial
go.drugbank.com/bio_entities/BE0002256TargetEnzymeHumans) and produce a new acyl-CoA. … Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate
Polypeptides: Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrialNKG2-A/NKG2-B type II integral membrane protein
go.drugbank.com/bio_entities/BE0010560TargetHumansDominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742). … In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell
Polypeptides: NKG2-A/NKG2-B type II integral membrane proteinSynonyms: NK cell receptor A, NKG2-A/B-activating NK receptorHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. … Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Products: POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION PARA ADMINISTRACIÓN OFTALMICA, HYLASE® DESSAU 150 IUDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14mlBosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.
Mixtures: OCUBRAX® SUSPENSION OFTALMICA, OCUBRAX® SUSPENSION OFTALMICACategories: Endothelin Receptor Antagonists, Cytochrome P-450 SubstratesClostridium tetani toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10583ApprovedInvestigationalClostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. … It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus.
Mixtures: 3 ANTIGEN, Neisvac-CProducts: TETAVAX single dose, suspension for injection in a prefilled syringe, T-VAC 0,5 ML IM ENJEKSIYON IÇIN SÜSPANSIYON IÇEREN AMPULMucopolysaccharidosis Type IVA
go.drugbank.com/conditions/DBCOND0060256Drugs: Elosulfase alfaSynonyms: MPS IV-A-Mucopolysaccharidosis IV-A, Morquio A DiseaseAcetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. … [A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Mixtures: N-ACETILCISTEÍNA 2 G + GUAYACOLATO DE GLICERILO 2 G JARABE, AMINOPLASMAL-5% E INFUSIONCategories: Compounds used in a research, industrial, or household settingCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971. … [A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acidInternational brands: L-KeflexDaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigationalDaptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Categories: P-glycoprotein substratesProducts: CUBICIN® 350 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, CUBICIN® 500 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE